TRIB Trinity Biotech PLC ADS

Trinity Biotech plc to Host Investor Call

Trinity Biotech plc to Host Investor Call

Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET

DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will host an investor call on Wednesday, January 31 at 8:30 AM ET to provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:Wednesday, January 31, 2024
Time:8:30 AM ET
United States:1-877-407-0784
International:1-201-689-8560
Conference ID:13744109
Webcast: for Webcast
CallMe™: for CallMe Feature



About Trinity Biotech


Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: .



Contact:Trinity Biotech plc

Des Fitzgerald

(353)-1-2769800
LifeSci Partners, LLC

Eric Ribner

(1)-646-751-4363

E-mail



EN
30/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE

Trinity Biotech Expands Global Rollout of High-Capacity Column System ...

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and ...

 PRESS RELEASE

Trinity Biotech Secures Major Regulatory Approval for Offshored and Ou...

Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization (W...

 PRESS RELEASE

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis...

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressiv...

 PRESS RELEASE

Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential ...

Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would facilitate the conversion of a portion of the Company...

 PRESS RELEASE

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the minimu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch